Applied Nutrition Plc/£APN
1D1W1MYTD1Y5YMAX
Capital at risk
About Applied Nutrition Plc
- Ticker
- £APN
- Sector
- Consumer Essentials
- Primary listing
- LSE
- Employees
- 270
- Headquarters
- Liverpool, United Kingdom
- Website
- appliednutrition.uk
APN Metrics
BasicAdvanced
£685M
24.86
£0.11
-
-
Price and volume
Market cap
£685M
52-week high
£3.56
52-week low
£1.60
Average daily volume
1.2M
Financial strength
Current ratio
3.459
Quick ratio
2.231
Long term debt to equity
0.032
Total debt to equity
0.045
Interest coverage (TTM)
195.00%
Profitability
EBITDA (TTM)
40.1
Gross margin (TTM)
46.12%
Net profit margin (TTM)
20.60%
Operating margin (TTM)
29.10%
Effective tax rate (TTM)
26.60%
Revenue per employee (TTM)
£500,000
Management effectiveness
Return on assets (TTM)
31.55%
Return on equity (TTM)
49.42%
Valuation
Price to earnings (TTM)
24.864
Price to revenue (TTM)
5.121
Price to book
9.84
Price to tangible book (TTM)
9.86
Price to free cash flow (TTM)
43.16
Free cash flow yield (TTM)
2.32%
Free cash flow per share (TTM)
0.064
Growth
Revenue change (TTM)
51.58%
Earnings per share change (TTM)
82.18%
What the Analysts think about APN
Analyst ratings (Buy, Hold, Sell) for Applied Nutrition Plc stock.
Analyst projections of the future price of Applied Nutrition Plc stock.
Bulls say / Bears say
Trading is materially ahead of expectations: FY26 revenue rose 50% to about £160m and adjusted EBITDA rose 40% to £43.3m. Management also guides to FY27 revenue of about £205m and EBITDA of £49m, both above consensus. (Applied Nutrition Investor Relations)
The Nutrablend acquisition gives Applied Nutrition local US manufacturing, faster lead times and more capacity in its largest expansion market. Management expects the business to add at least $30m of FY27 revenue and create scope for more own-brand sales over time. (Applied Nutrition Investor Relations)
The Mondelēz licensing agreement adds SOUR PATCH KIDS and SWEDISH FISH products to Applied Nutrition’s North American range. Using globally recognised consumer brands could improve product visibility and support the company’s US distribution push. (Applied Nutrition Investor Relations)
FY27 revenue is expected to grow faster than EBITDA, implying a slight margin decline. Applied Nutrition cites higher whey costs, a greater whey-product mix and a larger US contribution as the causes. (Applied Nutrition Investor Relations)
The Nutrablend deal may dilute group economics before the US operation scales: management expects high-single-digit EBITDA margins and about 65% of revenue from white-label manufacturing. The higher-margin own-brand opportunity is a longer-term objective, not an immediate benefit. (Applied Nutrition Investor Relations)
Sports nutrition is a crowded market where consumer tastes and brand loyalty can change quickly. Competition for retail shelf space and reliance on major channels could make growth harder to sustain. (Kalkine)
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2026.
APN Financial Performance
Revenues and expenses
APN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing APN
AllGBPEUR
Fund name | Fund size | £APN weighting |
|---|---|---|
Vanguard FTSE 250£VMID | £1.6B | 0.13% |
iShares FTSE 250£MIDD | £661M | 0.12% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.03% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.03% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.